Scientific briefing: Formulation-Monodisperse CR quetiapine microspheres
Posted: 4 August 2021 | ADARE Pharma Solutions | No comments yet
Adare’s Optimµm® technology offers a unique and efficient method of fabricating monodisperse microparticles at reduced development time.
The study herein uses Adare technology to fabricate monodisperse quetiapine microparticles to investigate the effects of formulation and size on the release profile of the API.
Related content from this organisation
- Maintaining EU MDR certification: a spotlight on post‑market clinical follow-up
- Formulation, Development & Delivery In-Depth Focus 2021
- Scientific briefing: Formulation-Monodisperse CR quetiapine microspheres
- Scientific briefing: Formulation of aqueous core poly (lactic acid) microcapsules
- Scientific briefing: Dissolution development Parvulet technology with oral tablets
Related topics
Analytical techniques, Biopharmaceuticals, Excipients, Formulation, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Research & Development (R&D)